Overview of the Enzymes That Build and Break Down the Body's Natural Cannabinoids
A comprehensive review of endocannabinoid metabolism identified multiple synthesis and degradation pathways for anandamide and 2-AG, with their metabolic enzymes emerging as drug targets for treating addiction and other conditions.
Quick Facts
What This Study Found
This review provided an integrative overview of the enzymes controlling endocannabinoid levels. Anandamide (AEA) biosynthesis involves multiple pathways including NAPE-PLD, secretory PLA2, and PLC. The endocannabinoid 2-AG is produced through phosphatidic acid phosphohydrolase, diacylglycerol lipase (DAGL), PI-PLC, and lyso-PLC.
Cellular uptake of endocannabinoids involves a putative membrane transporter or facilitated diffusion. Degradation is handled by FAAH (for anandamide) and both FAAH and MAGL (for 2-AG).
The review discussed therapeutic interventions targeting these metabolic enzymes, including applications for addiction treatment. By modulating the enzymes rather than the receptors, researchers could fine-tune endocannabinoid levels with potentially greater selectivity than directly activating or blocking cannabinoid receptors.
Key Numbers
AEA synthesis: NAPE-PLD, PLA2, PLC pathways. 2-AG synthesis: DAGL, PI-PLC, lyso-PLC, phosphatidic acid phosphohydrolase. Degradation: FAAH (AEA), MAGL and FAAH (2-AG). Transport: putative membrane transporter.
How They Did This
Integrative review of published research on endocannabinoid biosynthesis, transport, and degradation enzymes. Covered enzyme characterization, metabolic pathways, and potential therapeutic applications.
Why This Research Matters
Understanding the full metabolic machinery of the endocannabinoid system is essential for developing targeted drugs. Each enzyme in the pathway represents a potential drug target that could raise or lower endocannabinoid levels in specific ways, offering more precision than administering cannabinoids directly.
The Bigger Picture
The complexity of endocannabinoid metabolism, with multiple redundant pathways for both synthesis and degradation, explains why the system is so tightly regulated and why targeting individual enzymes can produce specific effects without completely disrupting the system.
What This Study Doesn't Tell Us
Rapidly evolving field where new enzymes and pathways were still being discovered. Some proposed pathways were based on limited evidence. The putative membrane transporter remained controversial. Therapeutic applications were largely preclinical.
Questions This Raises
- ?Which metabolic enzyme targets will prove most therapeutically useful?
- ?Can enzyme-targeted drugs achieve sufficient tissue selectivity to avoid systemic side effects?
Trust & Context
- Key Stat:
- Multiple synthesis and degradation pathways identified for each endocannabinoid, all potential drug targets
- Evidence Grade:
- Integrative review of molecular biology research. Provides comprehensive enzyme characterization but therapeutic applications were largely preclinical.
- Study Age:
- Published in 2007. Understanding of endocannabinoid metabolism has continued to expand, with new enzymes and pathways identified since this review.
- Original Title:
- Critical enzymes involved in endocannabinoid metabolism.
- Published In:
- Protein and peptide letters, 14(3), 237-46 (2007)
- Authors:
- Basavarajappa, Balapal S(4)
- Database ID:
- RTHC-00262
Evidence Hierarchy
Summarizes existing research on a topic.
What do these levels mean? →Frequently Asked Questions
How does the body control its own cannabinoid levels?
The body produces endocannabinoids (anandamide and 2-AG) on demand through specific enzymes and breaks them down quickly through other enzymes (FAAH and MAGL). This tight control allows precise regulation of cannabinoid signaling in different tissues.
Could targeting these enzymes lead to new medicines?
Yes. By inhibiting the enzymes that break down endocannabinoids (like FAAH or MAGL), researchers can boost the body's natural cannabinoid signaling. This approach is being explored for treating addiction, pain, anxiety, and other conditions.
Read More on RethinkTHC
- THC-amygdala-anxiety-brain
- anandamide-weed-withdrawal
- cannabinoid-receptors-recovery-time
- cannabis-developing-brain-teenagers
- cant-enjoy-anything-without-weed
- dopamine-recovery-after-quitting-weed
- endocannabinoid-system-explained-simply
- endocannabinoid-system-withdrawal
- nervous-system-weed-withdrawal-fight-flight
- teen-weed-use-under-18-effects-brain
- thc-brain-withdrawal
- thc-prefrontal-cortex-brain-effects
- weed-cortisol-stress-hormones
- weed-memory-loss-recovery
- weed-motivation-amotivational-syndrome
- weed-nervous-system-effects
- weed-reward-system-brain
Cite This Study
https://rethinkthc.com/research/RTHC-00262APA
Basavarajappa, Balapal S. (2007). Critical enzymes involved in endocannabinoid metabolism.. Protein and peptide letters, 14(3), 237-46.
MLA
Basavarajappa, Balapal S. "Critical enzymes involved in endocannabinoid metabolism.." Protein and peptide letters, 2007.
RethinkTHC
RethinkTHC Research Database. "Critical enzymes involved in endocannabinoid metabolism." RTHC-00262. Retrieved from https://rethinkthc.com/research/basavarajappa-2007-critical-enzymes-involved-in
Access the Original Study
Study data sourced from PubMed, a service of the U.S. National Library of Medicine, National Institutes of Health.
This study breakdown was produced by the RethinkTHC research team. We analyze and report published research findings without making health recommendations. All interpretations are based solely on the published abstract and study data.